Q-omics provides the consensus-scored ZC4H2 profile across patient tissues and cancer cell-line models. ZC4H2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, ZC4H2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ZC4H2 RNA expression shows 19,532 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUSC, KICH, and KIRP as cancer lineages where ZC4H2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC4H2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC4H2 survival associations across molecular data types. ZC4H2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC4H2 RNA expression–survival associations across cancer types. High ZC4H2 expression shows unfavorable associations in LUSC and LIHC, but favorable associations in KIRC, MESO, UVM and LGG. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LUSC as the clearest survival context for ZC4H2 RNA expression.
This table summarizes ZC4H2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZC4H2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC4H2 shows lower tumor expression in KICH, LUSC, THCA, KIRC and BRCA and higher tumor expression in LIHC. The KICH box plot shows higher ZC4H2 RNA expression in normal versus tumor tissue (log2 FC = −1.839, t-test p < 0.001).
This table shows molecular features associated with ZC4H2 in patient tissues and cancer cell lines. In patient samples, ZC4H2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC4H2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
